Professional career
Curriculum vitae
Since 2015
Head of Medical Oncology/Internal Medicine, St. Claraspital
2004-2014
Senior Physician Medical Oncology, Cantonal Hospital Liestal & St. Claraspita
2001-2004
Assistant physician in medical oncology
CHUV Lausanne, Cantonal Hospital Liestal & University Hospital Basel
1994-2000
Resident in Internal Medicine
University Hospital Basel, Cantonal Hospital Bruderholz, Cantonal Hospital Liestal & Hospital Thusis
1997
Promotion
1993
State examination
Memberships and commitments
List of memberships
Swiss Society of Internal Medicine (SGIM)
Swiss Society for Medical Oncology (SGMO)
European Society of Medical Oncology (ESMO)
Swiss Working Group for Lymphomas (SAKK)
Swiss Working Group for Breast Cancer (SAKK)
Publications
- Harms W., Geretschläger A., Cescato C., Buess M., Köberle D., Asadpour B. Current Treatment of Isolated Locoregional Breast Cancer Recurrences. Breast Care 2015;10:265-271.
- Cescato-Wenger C & Ruszat R, 2010. modern therapy of renal cell carcinoma, Clara Aktuell No. 31:5-10.
- Hess V, Pratsch S, Potthast S, Lee L, Winterhalder R, Widmer L, Cescato C, Lohri A, Jost L, Stillhart P, Pestalozzi B, Herrmann R, 2010.Combining gemcitabine, oxaliplatin and capecitabine (GEMOXEL) for patients with advanced pancreatic carcinoma (APC): a phase I/II trial. Ann Oncol.;21(12):2390-5.
- Klaeser, B, Nitzsche, E, Schuller, J C, Koberle, D, Widmer, L, Balmer-Majno, S, Hany, T, Cescato-Wenger, C, Brauchli, P, Zund, M, Pestalozzi, B C, Caspar, C, Albrecht, S, von Moos, R, and Ruhstaller, T, 2009. Limited predictive value of FDG-PET for response assessment in the preoperative treatment of esophageal cancer: results of a prospective multi-centre trial (SAKK 75/02). Oncology; 32:724-30.
- Wenger C, Stern M, Herrmann R, Rochlitz Ch, Pless M, 2005. rituximab plus gemcitabine: a therapeutic option for elderly or frail patients with aggressive non Hodgkin's lymphoma? Leuk Lymphoma;46(1):71-5.
- Wenger C, 2001, Multiple morbidity in a patient (87 years old): Praxis (Bern 1994);18;90(3):75-8.